What question did this study set out to answer?

April 25, 2026

Economic Evaluation of Sodium-Glucose Cotransporter-2 Inhibitors in Patients with Heart Failure with Preserved or Mildly Reduced Ejection Fraction: A Systematic Review.

MRMohsen RezaeianRafsanjan University of Medical Sciences MNMostafa NasirzadehRafsanjan University of Medical Sciences MTMahsa Tashakori-MiyanroudiMazandaran University of Medical Sciences

Key Points

This evaluation aims to assess the cost-effectiveness of sodium-glucose cotransporter-2 inhibitors in patients with heart failure and varying ejection fraction.
Conducted a systematic review comparing SGLT2 inhibitors to standard of care.
Focused on patients with heart failure with preserved or mildly reduced ejection fraction.
Adding SGLT2 inhibitors to standard of care is cost-effective in the target population.
Further studies comparing dapagliflozin and empagliflozin are required.

Abstract

Study results indicate that adding SGLT2i to SoC is cost-effective in patients with HFpEF or HFmrEF. Moreover, further studies comparing dapagliflozin and empagliflozin in this patient group are needed.

AIに質問

Bookmark

View Full Paper